Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Baxter BioPharma Solutions and Moderna Announce Agreement for Fill\/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Alvotech","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alvotech Completes Second Round of a US$100 Million Private Placement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocon Biologics\u2019 Partner Receives Approval for Human Insulin for IV Infusion","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Biosimilar","date":"April 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"United Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baxter Launches Zosyn Premix in US","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Spectral Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.0 million","newsHeadline":"Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Baxter Healthcare Corporation

    Menu

    Baxter Healthcare Corporation

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Baxter Healthcare Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.

              Details:

              Norepinephrine Bitartrate is an adrenergic receptor agonist, small molecule drug candidate. Along with Dextrose it is indicated for the treatment of severe, acute hypotension.

              Lead Product(s): Norepinephrine Bitartrate,Dextrose

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 11, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Baxter Healthcare Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation

              Details:

              Through agreement, Baxter’s exclusive rights to commercialize Toraymyxin (polymyxin B), a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by Spectral’s Endotoxin Activity Assay.

              Lead Product(s): Polymyxin B Sulfate

              Therapeutic Area: Infections and Infectious Diseases Product Name: Toraymyxin

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Spectral Medical

              Deal Size: Undisclosed Upfront Cash: $5.0 million

              Deal Type: Agreement February 21, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Baxter Healthcare Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Baxter Launches Zosyn Premix in US

              Details:

              Zosyn is a combination of piperacillin sodium, which exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria and tazobactam sodium having activity against bacteria due to its reduced affinity to penicillin-binding proteins.

              Lead Product(s): Piperacillin Sodium,Tazobactam Sodium

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Zosyn

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Baxter Healthcare Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure

              Details:

              As part of the collaboration, Miromatrix has created a new liver therapy called miroliverELAP that combines a Miromatrix single-use bioengineered liver with Baxter’s PrisMax system for patients with acute liver failure (ALF) in need of organ support therapies.

              Lead Product(s): MiroliverELAP

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MiroliverELAP

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Recipient: United Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Baxter Healthcare Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Biocon Biologics’ Partner Receives Approval for Human Insulin for IV Infusion

              Details:

              Inpremzia is an approved medicine used to treat people with diabetes who need insulin to keep their blood glucose (sugar) level controlled. It contains the active substance insulin human.

              Lead Product(s): Insulin Lispro

              Therapeutic Area: Endocrinology Product Name: Inpremzia

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Biocon

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Baxter Healthcare Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Alvotech Completes Second Round of a US$100 Million Private Placement

              Details:

              Proceeds will be used for the development of companies lead drug AVT02. As part of the first round Shinhan from Korea, Baxter Healthcare SA from the US and ATHOS (Strüngmann Family Office) from Germany invested in Alvotech.

              Lead Product(s): Adalimumab

              Therapeutic Area: Dermatology Product Name: AVT02

              Highest Development Status: Phase III Product Type: Large molecule

              Recipient: Alvotech

              Deal Size: $100.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement March 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Baxter Healthcare Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Baxter BioPharma Solutions and Moderna Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.

              Details:

              Baxter BioPharma Solutions will provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 Vaccine in 2021.

              Lead Product(s): mRNA-1273

              Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1273

              Highest Development Status: Approved Product Type: Vaccine

              Partner/Sponsor/Collaborator: Moderna Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY